Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne

This study has been completed.
Information provided by:
Galderma Laboratories, L.P. Identifier:
First received: May 2, 2007
Last updated: March 28, 2008
Last verified: March 2008
To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream

Condition Intervention Phase
Acne Vulgaris
Drug: Adapalene Gel, 0.1%
Drug: Tazarotene Cream, 0.1%
Drug: Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-Week Treatment Switched to Tazorac® Cream, 0.1% 6-Week Treatment in Patients With Acne Vulgaris

Resource links provided by NLM:

Further study details as provided by Galderma Laboratories, L.P.:

Primary Outcome Measures:
  • Efficacy - total lesion counts [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Safety - tolerability assessments and adverse event reporting [ Time Frame: 12 weeks ]

Enrollment: 302
Study Start Date: February 2006
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Differin® Gel, 0.1% for 12 weeks
Drug: Adapalene Gel, 0.1%
Apply once daily in the evening for 12 weeks
Other Name: Differin® Gel, 0.1%
Active Comparator: 2
Tazorac® Cream, 0.1% for 12 weeks
Drug: Tazarotene Cream, 0.1%
Apply once daily in the evening for 12 weeks
Other Name: Tazorac® Cream, 0.1%
Active Comparator: 3
Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
Drug: Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
Other Name: Differin® Gel, 0.1% and Tazorac® Cream, 0.1%

Detailed Description:
Same as above.

Ages Eligible for Study:   12 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with a minimum of 20 inflammatory lesions (papules and pustules) on the face
  • Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open comedones and closed comedones) on the face, excluding the nose

Exclusion Criteria:

  • Subjects with more than 3 nodulo-cystic lesions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00469755

United States, California
Therapeutics Clinical Research
San Diego, California, United States, 92123
United States, Michigan
Henry Ford Medical Center-Dept. of Dermatology
Detroit, Michigan, United States, 48202
United States, Minnesota
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
United States, New York
State University of New York Downstate Medical Center-Dept. of Dermatology
Brooklyn, New York, United States, 11203
United States, Ohio
Dermatology Research Associates
Cincinnati, Ohio, United States, 45230
United States, Oregon
Phoebe Rich, MD & Associates
Portland, Oregon, United States, 97210
United States, Pennsylvania
Milton S. Hershey Medical Center Center-Div. of Dermatology
Hershey, Pennsylvania, United States, 17033-0850
United States, Texas
DermResearch, Inc.
Austin, Texas, United States, 78759
J & S Studies, Inc.
Bryan, Texas, United States, 77802
Stephens & Associates
Carrollton, Texas, United States, 75006
United States, Utah
Dermatology Research Center
Salt Lake City, Utah, United States, 84124
United States, Virginia
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Galderma Laboratories, L.P.
Study Director: Ronald W Gottschalk, MD Galderma Laboratories, L.P.
  More Information

Responsible Party: Ronald W. Gottschalk, MD / Medical Director, Galderma Laboratories, L.P. Identifier: NCT00469755     History of Changes
Other Study ID Numbers: US10026
Study First Received: May 2, 2007
Last Updated: March 28, 2008

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Nicotinic Acids
Dermatologic Agents
Keratolytic Agents
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on April 28, 2017